NCT02330406View on ClinicalTrials.gov

Randomized Evaluation of Anagliptin Versus Sitagliptin On Low-density lipoproteiN Cholesterol in Diabetes Trial

PHASE4CompletedINTERVENTIONAL

Enrollment

353

Participants

Timeline

Start Date

April 30, 2015

Primary Completion Date

January 31, 2018

Study Completion Date

March 31, 2019

Conditions

Dipeptidyl-Peptidase 4 InhibitorsLDL CholesterolGlycosylated HemoglobinDiabetes MellitusCoronary Disease

Interventions

DRUG

Anagliptin

Suiny 100 mg

DRUG

Sitagliptin

Januvia 50 mg Glactiv 50 mg

Trial Locations (1)

901-0243

Department of Cardiovascular Medicine, Tomishiro Central Hospital, Tomishiro

All Listed Sponsors

lead

Institute for Clinical Effectiveness, Japan

OTHER

NCT02330406 - Randomized Evaluation of Anagliptin Versus Sitagliptin On Low-density lipoproteiN Cholesterol in Diabetes Trial | Biotech Hunter | Biotech Hunter